Abbott Laboratories (ABT) fell 8.49 percent to $120.56 on Tuesday, despite no company-specific developments. The decline occurred as broader market discussions highlighted growth prospects in the global biochip market, projected to reach $27.8 billion by 2029 from $16.1 billion in 2024, driven by demand for advanced diagnostics and personalized medicine.
ABT opened at $126.55 and traded between $119.77 and $126.86 during the session, compared to a prior close of $131.74 on the New York Stock Exchange. Volume surged to 18.5 million shares, well above its average of 6.1 million. The stock's 52-week range stands at $99.71 to $141.23.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.